Trial reportJCO precision oncology2022
Phase II Study of Taselisib in
Erratum issuedOpen access · greenAbstract readClinical Trial, Phase II
In one paragraph
Trial report in JCO precision oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Precision Oncology Clinical Trials: A Systematic Review of Phase II Clinical Trials with Biomarker-Driven, Adaptive Design.Cancer research and treatment · 2024Pooled it
- A phase II study to evaluate the efficacy of commercially available molecularly matched targeted therapies in the second-line setting.The oncologist · 2026Trial
- Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H.JCO precision oncology · 2025Trial
- Review
- Article
- Non-small cell lung cancer after EGFR-TKI resistance: from drug resistance mechanisms to precision interventions.Frontiers in pharmacology · 2026Review
- From PIK3CA Mutations to Rational PI3K Inhibition for the Treatment of Colorectal Cancer.Molecular diagnosis & therapy · 2026Review
- Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131).Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Tumour-agnostic kinase inhibitors.Nature reviews. Drug discovery · 2025Review
- Deciphering of intra-tumoural heterogeneity and the interplay between metastasis-associated meta-program and myofibroblasts in gastric cancer.Clinical and translational medicine · 2025Article
- Targeting PI3K signaling in Lung Cancer: advances, challenges and therapeutic opportunities.Journal of translational medicine · 2025Review
- The PIK3CA gene and its pivotal role in tumor tropism of triple-negative breast cancer.Translational oncology · 2024Review
- Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions.Molecular cancer · 2024Review
- Anticancer potential of grifolin in lung cancer treatment through PI3K/AKT pathway inhibition.Heliyon · 2024Article
- Agnostic Administration of Targeted Anticancer Drugs: Looking for a Balance between Hype and Caution.International journal of molecular sciences · 2024Review
- PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment.International journal of molecular sciences · 2024Review
- Tumor-Specific Activity of Precision Medicines in the NCI-MATCH Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers.International journal of molecular sciences · 2024Review
- Heterogeneity in precision oncology.Cambridge prisms. Precision medicine · 2024Review
- Home-run trials for rare cancers: giving the right drug(s) to the right patients at the right time and in the right place.NPJ precision oncology · 2023Review
Corrections and comments
- Erratum issuedErratum.2022
Authors and funding
25 authors at 17 institutions in 1 country.
Ian E KropMedical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-6380-5944
Opeyemi A JegedeDana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA.ORCID 0000-0003-1763-8214
Juneko E Grilley-OlsonUniversity of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC.ORCID 0000-0002-1896-7020
Josh D LauringJohns Hopkins School of Medicine, Baltimore, MD.ORCID 0000-0002-4312-704X
Edith P MitchellThomas Jefferson University, Philadelphia, PA.ORCID 0000-0001-8528-4716
James A ZwiebelNational Cancer Institute, Bethesda, MD.ORCID 0000-0003-4455-8789
Robert J GrayDana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA.ORCID 0000-0002-5724-4917
Victoria WangDana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA.
Lisa M McShaneNational Cancer Institute, Bethesda, MD.ORCID 0000-0001-8195-3206
Larry V RubinsteinNational Cancer Institute, Bethesda, MD.ORCID 0000-0002-9720-9737
David PattonNational Cancer Institute, Bethesda, MD.ORCID 0000-0003-3855-0166
P Mickey WilliamsFrederick National Laboratory for Cancer Research, Frederick, MD.ORCID 0000-0002-3309-5988
Stanley R HamiltonCity of Hope Comprehensive Cancer Center, Duarte, CA.ORCID 0000-0002-8331-1052
Scott A KonoColorado Permanente Medical Group, Lone Tree, CO.
James M FordStanford University, Stanford, CA.ORCID 0000-0002-2513-7025
Agustin A GarciaLouisiana State University Health Science Center, New Orleans, LA.
Xingwei D SuiProvidence Regional Cancer System, Lacey, WA.
Robert D SiegelBon Secours St Francis Hospital, Greenville, SC.ORCID 0000-0001-9837-9730
Brian M SlomovitzUniversity of Miami, Miami, FL.
Barbara A ConleyNational Cancer Institute, Bethesda, MD.ORCID 0000-0002-1445-1684
Carlos L ArteagaUniversity of Texas Southwestern Medical Center, Dallas, TX.
Lyndsay N HarrisNational Cancer Institute, Bethesda, MD.
Peter J O'DwyerUniversity of Pennsylvania, Philadelphia, PA.
Alice P ChenNational Cancer Institute, Bethesda, MD.ORCID 0000-0002-2919-4326
Keith T FlahertyMassachusetts General Hospital, Boston, MA.ORCID 0000-0002-3402-0478
National Cancer Institute · USECOG-ACRIN Cancer Research Group · USCity of Hope · USDana-Farber Cancer Institute · USFlorida International University · USFrederick National Laboratory for Cancer Research · USJohns Hopkins University · USKaiser Permanente Lone Tree Medical Offices · USLouisiana State University Health Sciences Center New Orleans · USMassachusetts General Hospital · USProvidence College · USStanford University · USSt. Francis Hospital · USThe University of Texas Southwestern Medical Center · USThomas Jefferson University · USUniversity of North Carolina at Chapel Hill · USUniversity of Pennsylvania · US
Funding
NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8MProject-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer · 2014 to 2026
$167.6MSWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1MStatistics CoreU10CA180794 · NCI · DANA-FARBER CANCER INST · PI PAUL J CATALANO · 2014 to 2026
$111.2MKaiser Permanente NCI National Community Oncology Research Program, NCORPUG1CA189821 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI Jennifer Marie Suga · 2014 to 2026
$44.4MECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · 2015 to 2026
$41.1MSoutheast Clinical Oncology Research Consortium, Inc. (SCOR)UG1CA189858 · NCI · SOUTHEAST CLINICAL ONCOL RES CONSORTIUM · PI Judith O Hopkins, William J Irvin · 2014 to 2026
$38.8MThe Pacific Cancer Research Consortium (PCRC), an NCORP Community SiteUG1CA189953 · NCI · SWEDISH MEDICAL CENTER, FIRST HILL · PI Alison Katherine Conlin, Charles Drescher · 2014 to 2026
$27.4MGulf South Minority/Underserved Clinical Trials Network (Gulf South M/U CTN)UG1CA189854 · NCI · LSU HEALTH SCIENCES CENTER · PI AUGUSTO C. OCHOA · 2014 to 2026
$27.1MUT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP) UG1UG1CA233329 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KELLY K HUNT, CHELSEA Camille PINNIX · 2019 to 2026
$11.1MNCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareUG1CA233180 · NCI · DANA-FARBER CANCER INST · PI Harold John Burstein · 2019 to 2026
$8.6MUT Southwestern NCI National Clinical Trials Network (NCTN) LAPS - Supplemental Funds YR4UG1CA233302 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI David Eric Gerber · 2019 to 2026
$6.4MNCI NIH HHS U10 CA180794NCI NIH HHS U10 CA180820NCI NIH HHS U10 CA180868NCI NIH HHS U10 CA180888NCI NIH HHS U24 CA196172NCI NIH HHS UG1 CA189821NCI NIH HHS UG1 CA189854NCI NIH HHS UG1 CA189858NCI NIH HHS UG1 CA189953NCI NIH HHS UG1 CA233180NCI NIH HHS UG1 CA233196NCI NIH HHS UG1 CA233302NCI NIH HHS UG1 CA233329NCI NIH HHS UG1 CA233341NCI NIH HHS UG1 CA233373
Abstract
purpose
methodsEligible patients had tumors with an activating
resultsSeventy patients were enrolled, and 61 were eligible and initiated protocol therapy. Types of
conclusionIn this study, taselisib monotherapy had very limited activity in a heterogeneous cohort of heavily pretreated cancer patients with
Indexed as
Carcinoma, Squamous CellLung NeoplasmsClass I Phosphatidylinositol 3-KinasesHumansImidazolesNational Cancer Institute (U.S.)OxazepinesPhosphatidylinositol 3-KinasesUnited States2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamideClass I Phosphatidylinositol 3-KinasesImidazolesOxazepinesPhosphatidylinositol 3-KinasesPIK3CA protein, human
Identifiers
What Socratic holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.